A Phase 1 interventional study of Filsuvez topical gel: 10% birch triterpenes in Dystrophic Epidermolysis Bullosa and Junctional Epidermolysis Bullosa, sponsored by Medical University of South Carolina. Not yet recruiting at 1 site in United States. Open to participants aged 0 Days to 5 Months. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Medical University of South Carolina · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States — 13 open to participants now, 17 under way, 4 of them phase 3. Epidermolysis Bullosa Dystrophica · United States.
Among the 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States, this one is the 5th largest by planned enrollment of the 33 interventional ones that give a count, is the only one that started in 2027, is one of 4 in phase 1, reaches primary completion later than 13 of the 16 other live ones, and was the 46th registered.
79 studies on the registry are indexed under Epidermolysis Bullosa Dystrophica; 22 are open to participants now.
Browse Epidermolysis Bullosa Dystrophica studies →13 of the 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States are open now. Recruiting first, the newest first:
Xinnate AB · Sites in United States, France, Greece and 4 more countries
Ages 4+
M. Peter Marinkovich · Sites in United States
Ages 6+
Abeona Therapeutics, Inc · Sites in United States
Krystal Biotech, Inc. · Sites in United States
Ages 6 mo+
Chiesi Farmaceutici S.p.A. · Sites in United States, France, Germany and 3 more countries
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Epidermolysis Bullosa Dystrophica studies recruiting now, 13 (76%) set no upper age limit and 3 (18%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 0 Days to 5 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 18 · Phase 3 8
First in 2007; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is above the median of 9 across 56 interventional studies indexed under Epidermolysis Bullosa Dystrophica.
Median enrollment 8 across the 33 interventional studies, 29 across the 13 observational. Of the 24 that completed or were terminated, 11 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 166 are open to participants now.
Of its 131 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
Medical University of South Carolina has 1 study filed under Epidermolysis Bullosa Dystrophica — fewer than ten, so there is no comparison to draw.
4 of the studies in Epidermolysis Bullosa Dystrophica with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07016750Phase 3Krystal Biotech, Inc.A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | 2026-12 |
| NCT06892639Phase 3Castle Creek Biosciences, LLC.Evaluation of D-Fi for the Treatment of Wounds Due to DEB | 2027-09 |
| NCT06834035M. Peter MarinkovichTargeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa | 2027-03 |
| NCT06594393Xinnate ABA Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study will evaluate the safety and tolerability of Filsuvez, a topical gel, in newborns and infants younger than 6 months with dystrophic or junctional epidermolysis bullosa. Filsuvez is approved for patients 6 months of age and older but has not been studied in this younger population. Participants will receive Filsuvez for 180 days and will be followed with clinical assessments, laboratory testing, caregiver questionnaires, telephone contacts, and standardized photographs. The study will also explore changes in wound size, disease activity, pain, and family burden during and after treatment.
Epidermolysis bullosa is a rare genetic disorder characterized by skin fragility, blistering, and chronic wounds. Newborns and young infants with dystrophic or junctional epidermolysis bullosa have limited treatment options and may be at increased risk for infection and other complications. This open-label, multicenter pilot study will enroll up to 20 participants who are 5 months of age or younger at enrollment. Participants will receive topical Filsuvez with standard wound-dressing changes for 180 days. Safety will be monitored through adverse-event and concomitant-medication assessments, clinical evaluations, and laboratory tests including complete blood count, basic metabolic panel, and inflammatory markers. Follow-up assessments include standardized full-body photography, disease activity and body-surface-area assessments, wound measurements, pain assessment, and caregiver-reported family burden. Participants will be followed during treatment and for 180 days after the treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Filsuvez topical gel: 10% birch triterpenes will be applied with a 1mm layer to the affected wound surface and cover the wound dressing. Filsuvez should be applied directly to the dressing so that the topical gel is in direct contact with the wound. Filsuvez can be applied with standard of care bandage changes, at least every 4 days.
Drug: Filsuvez topical gel: 10% birch triterpenes
Filsuvez topical gel: 10% birch triterpenes w/w in a colorless, slightly yellow gel supplied in 25 mL sterile tubes.
the safety and tolerability of Filsuvez
Our primary objective is to evaluate the safety and tolerability of Filsuvez for neonates and infants under six months of age with dystrophic or junctional EB (DEB or JEB). We plan to conduct monthly phone calls to assess adverse events and concomitant meds.
Time frame: 450 days-including follow up
Evaluate preliminary efficacy and quantify the reduction in wound size and burden from baseline to 45, 90, and 180 days
Our secondary objective is to evaluate preliminary efficacy and quantify the reduction in wound size and burden from baseline to 45, 90, and 180 days during the treatment period using full body photographic skin assessment, ensuring that a ruler with cm is included in the photograph for later analysis.
Time frame: 180 days
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epidermolysis Bullosa Dystrophica →
Medical University of South Carolina →